EQS-News / 22/03/2022 / 08:00 UTC+8 Achieved Record-High Turnover and EGF Products Recorded Strong ReboundSuccessful Expansion Into Ophthalmology and Other Potential Therapeutic Areas [21 March 2022 - Hong Kong] A fully integrated biopharmaceutical company - Uni-Bio Science Group Limited ("Uni-Bio Science".
®. Next step, the Company will focus on the launch and successful commercialization of BOSHUTAI
®. As manufacturing cost leadership is essential for the success of the product, the company is already working with a number of strategic partnerships across the supply chain to ensure BOSHUTAI
® is manufactured at the lowest cost possible. Additionally, the Company successfully held the BOSHUTAI
® launch conference on 11 December 2020, where more than 60 commercial partners attended the event.
Acarbose was first developed by Bayer in 1975 and launched in Switzerland in 1986 (trade name: Glucobay
®). As the first FDA-approved alpha-glucosidase inhibitor in the world, it entered China in 1994 and is now recommended as a first-line drug for T2D. Acarbose is sold far better in China and Asia than in other western countries due to the high carbohydrate content in Asian cuisine.